Mono Pharmacare (NSE:MONOPHARMA) Stock Based Compensation: ₹0 Mil (TTM As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:MONOPHARMA Mono Pharmacare Ltd NSE:MONOPHARMA
12 GF Score
Price ₹7.85
! 6 Warning Signs
View Full Analysis

What is Mono Pharmacare Stock Based Compensation?

Mono Pharmacare NSE:MONOPHARMA 12 Stock Based Compensation is ₹0 Mil as of Sep. 2025. GuruFocus rates NSE:MONOPHARMA with a GF Score™ of 12/100. The stock has 6 warning signs investors should review.

Mono Pharmacare's Stock Based Compensation for the six months ended in Sep. 2025 was ₹0 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Sep. 2025 was ₹0 Mil.

Mono Pharmacare Stock Based Compensation Related Terms

Mono Pharmacare Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Mono Pharmacare's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mono Pharmacare Stock Based Compensation Chart

Mono Pharmacare Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25
Stock Based Compensation
0.00 0.00 0.00 0.00 0.00

Mono Pharmacare Semi-Annual Data
Mar21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00
NSE:MONOPHARMA
12GF Score
Mono Pharmacare Ltd NSE:MONOPHARMA
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mono Pharmacare Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Sep. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₹0 Mil.

What does a Stock Based Compensation of ₹0 Mil mean?
Mono Pharmacare (NSE:MONOPHARMA) has a Stock Based Compensation of ₹0 Mil as of Sep. 2025. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Mono Pharmacare and its competitors.
Is Mono Pharmacare's Stock Based Compensation too high?
Mono Pharmacare's current Stock Based Compensation is ₹0 Mil. Overall, Mono Pharmacare has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Mono Pharmacare's Stock Based Compensation compare to competitors?
Mono Pharmacare's Stock Based Compensation of ₹0 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Healthcare Providers & Services company?
A good Stock Based Compensation depends on the Healthcare Providers & Services industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Mono Pharmacare and its competitors. Mono Pharmacare's current Stock Based Compensation is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mono Pharmacare stock overvalued right now?
Mono Pharmacare (NSE:MONOPHARMA) has a current Stock Based Compensation of ₹0 Mil. The current Stock Based Compensation is ₹0 Mil. Mono Pharmacare's overall GF Score™ is 12/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Mono Pharmacare (NSE:MONOPHARMA), the current Stock Based Compensation is ₹0 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Mono Pharmacare Business Description

Address 1A, Krinkal Apartment, Opposite Mahalaxmi Temple, Paldi, Ahmedabad, GJ, IND, 380007
Mono Pharmacare Ltd distributes a broad range of pharmaceutical products across India. Its portfolio includes antibiotics, antifungal medicines, cough and cold remedies, antacids, analgesics, nutraceuticals, skincare, antiseptics, cardiac and diabetic drugs, and cosmetic items. The company operates through contract manufacturing, sourcing products from various manufacturers and supplying them to healthcare providers and pharmacies. Revenue is generated through the sales and distribution of these pharmaceutical and healthcare products in the Indian market.
12GF Score

Get the complete analysis for NSE:MONOPHARMA

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹7.85
Price